PCLOF (PharmaCielo) Current Accrued Expense: $3.80 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PharmaCielo Current Accrued Expense?

PharmaCielo PCLOF +1.94% Current Accrued Expense is $3.80 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

PharmaCielo's Current Accrued Expense for the quarter that ended in Dec. 2025 was $3.80 Mil.

PharmaCielo's quarterly Current Accrued Expense declined from Jun. 2025 ($6.07 Mil) to Sep. 2025 ($4.14 Mil) and declined from Sep. 2025 ($4.14 Mil) to Dec. 2025 ($3.80 Mil).

PharmaCielo's annual Current Accrued Expense declined from Dec. 2022 ($4.50 Mil) to Dec. 2023 ($4.20 Mil) and declined from Dec. 2023 ($4.20 Mil) to Dec. 2024 ($3.76 Mil).

PharmaCielo Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for PharmaCielo's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCielo Current Accrued Expense Chart

PharmaCielo Annual Data
Trend Aug17 Aug18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
Get a 7-Day Free Trial 9.14 6.04 4.50 4.20 3.76

PharmaCielo Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.71 3.76 6.07 4.14 3.80

PharmaCielo Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $3.80 Mil mean?
PharmaCielo (PCLOF) has a Current Accrued Expense of $3.80 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on PharmaCielo and its competitors.
Is PharmaCielo's Current Accrued Expense too high?
PharmaCielo's current Current Accrued Expense is $3.80 Mil.
How does PharmaCielo's Current Accrued Expense compare to ZTS and UTHR?
PharmaCielo's Current Accrued Expense of $3.80 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on PharmaCielo and its competitors. PharmaCielo's current Current Accrued Expense is $3.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.22, compared to a current price of $0.04 — trading 80.9% below its estimated fair value. The current Current Accrued Expense is $3.80 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current Current Accrued Expense is $3.80 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCielo Business Description

Other Exchanges PCLO:Canada
Address 82 Richmond Street East, Suite 805, Toronto, ON, CAN, M5C 1P1
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.